# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRESIDENT’S MESSAGE</td>
<td>3</td>
</tr>
<tr>
<td>PRESENTATION INFORMATION</td>
<td>4</td>
</tr>
<tr>
<td>PROGRAM HIGHLIGHTS</td>
<td>5</td>
</tr>
<tr>
<td>FEATURED PRESENTERS</td>
<td>6</td>
</tr>
<tr>
<td>PROGRAM, STEERING, AND NIA COMMITTEE CHAIRS</td>
<td>17</td>
</tr>
<tr>
<td>NIA COMMITTEE</td>
<td>18</td>
</tr>
<tr>
<td>PROGRAM COMMITTEE</td>
<td>18</td>
</tr>
<tr>
<td>STEERING COMMITTEE</td>
<td>20</td>
</tr>
<tr>
<td>ASCP BOARD OF DIRECTORS</td>
<td>21</td>
</tr>
<tr>
<td>Awardees</td>
<td>22</td>
</tr>
<tr>
<td>JOIN THE CONVERSATION</td>
<td>26</td>
</tr>
<tr>
<td>UNRESTRICTED EDUCATIONAL GRANTS</td>
<td>27</td>
</tr>
<tr>
<td>CONTINUING EDUCATION</td>
<td>28</td>
</tr>
<tr>
<td>SAVE THE DATE: 2022 ANNUAL MEETING IN SCOTTSDALE</td>
<td>29</td>
</tr>
</tbody>
</table>
June 2021

Dear Colleagues,

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our 2021 Virtual Annual Meeting. Once again, we cannot gather in the traditional way this year, however, I am excited to offer a virtual option that will continue the tradition of presenting groundbreaking information in psychopharmacology. I want to thank you for continuing to stay with us during these unprecedented times.

Throughout the last year we have all faced challenges, personally and professionally, but I am proud of all the work ASCP members have been able to accomplish in such unprecedented times. During the 2021 Annual Meeting it is our goal to present state of the art information that will enable you to continue to navigate these unchartered waters while providing high levels of care with confidence.

The ASCP is committed to finding and testing new therapeutics for our patients. We want to advance not only the field of psychopharmacology but treatment research. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials. I am sure that we will see presentations and posters during this meeting that will become important methods for caring for our patients well into the future. I am thrilled that we will be able to present all the most anticipated and highly regarded sessions of past Annual Meetings including the Federal Agency Updates, Regulatory Plenary, Clinical Updates in Psychopharmacology, Pharmaceutical Pipelines, and virtual poster sessions. The keynote plenary brings together renowned experts that will be discussing Integrating New and Novel Treatments into Clinical Practice and Education.

We at the American Society of Clinical Psychopharmacology value and pursue a climate of equity and inclusion that is embraced and championed by ASCP Leadership. ASCP continues to aspire to become an exemplary leader in creating an inclusive and welcoming environment wherein everyone can learn, develop, innovate, and flourish. Consistent with this commitment, we will offer a special session during the ASCP 2021 Annual Meeting with ASCP Senior leaders discussing the measures ASCP is taking to become a more inclusive society. I encourage you to join this timely and important session.

On a final note, I would like to take this opportunity to personally thank the ASCP Officers, the Steering Committee led by Susan Kornstein, M.D., and Mark Rapaport, M.D., and the Program Committee led by Erika Saunders, M.D., and Lee Cohen, M.D., not only for their dedication to planning the 2021 Annual Meeting but developing valuable content to ensure we continue to advance the science and practice of clinical psychopharmacology in new and meaningful ways despite the challenges we have all faced throughout the past year. At the conclusion of day one, I invite you to join several ASCP Board of Directors and ASCP Senior Members for a virtual cocktail hour which will allow you the opportunity to meet respected leaders in the society and field.

It is our hope that this meeting brings you facts and information to help you integrate new and novel treatments into clinical practice helping the millions that suffer with mental illness. On behalf of the ASCP Board of Directors, thank you for joining us this week. I hope you enjoy the meeting. And I want to welcome Dr. Les Citrome as our Next President of the Society.

Sincerely,

Madhukar Trivedi, M.D.
ASCP President
The 2021 ASCP Annual Meeting is a VIRTUAL experience. All the science sessions will be hosted on through the virtual platform and Zoom and will run June 1 – 4, 2021. All session links will be shared with presenters and available to attendees through the conference platform. The platform will open a week prior to the meeting for attendees to familiarize themselves with it.

Please note that sessions will be recorded, unless otherwise noted, and will remain live in a conference library through July 31, 2021. You will only be available to claim continuing education hours through this date as well.

**If you have questions before or during the conference, we encourage you to:**
1) Use the Q&A feature to ask a question of the presenter
2) Email info@ascpp.org with additional questions or concerns. Calling the ASCP Executive Office is not advised as the response time may be delayed during the conference.
3) Visit the Help Desk or Speaker Ready Room during the conference for immediate assistance from ASCP staff.

All poster presentations will be available in the e-poster gallery for conference attendees to view at their convenience. [Click here to access the gallery.](#) Poster presenters that provided a link can be contacted during their assigned session using the “Join Online Meeting” link. This link will bring you to the presenter’s personal teleconference meeting room. Presenters are asked to be in attendance during the poster session to answer questions about your poster. Attendees can communicate with presenters that did not provide a teleconference link via the poster discussion board or attendees chat feature.

**POSTER SESSION HOURS**

Wednesday, June 2, 2021: 10:00am – 11:00am EDT
Thursday, June 2, 2021: 9:00am – 10:00am EDT

ASCP leadership is committed to providing state-of-the-art education on new developments in psychopharmacology for psychiatrists and other professionals in the treatment of psychiatric disorders. The Program and Steering Committees have curated a virtual program to include many of the highly regarded sessions of past Annual Meetings.
Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2021 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

- **2021 Program Highlights**
  - **Tuesday, June 1st:**
    - Pharma Pipeline
  - **Wednesday, June 2nd:**
    - Clinical Updates in Psychopharmacology
    - Poster Session I
  - **Thursday, June 3rd:**
    - Poster Session II
    - Keynote Plenary
    - ASCP Discussion of Strategies For Becoming a More Inclusive Organization
  - **Friday, June 4th:**
    - Regulatory Plenary
    - Federal Agency Updates Plenary
  - **Enduring Material**
    - 2021 ASCP Psychopharmacology Update: State-of-the-Art Spring Meeting recorded lectures
    - 2020 ASCP Psychopharmacology Update: State-of-the-Art Fall Meeting recorded lectures
  - **Clinical Track** – Sessions focused on topics of immediate clinical relevance

- **Organization**
  - The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
    - The Steering Committee organizes the meeting.
    - The Program Committee evaluates submitted proposals and develops program innovations.
  - Federal agency collaborations:
    - NIAAA – National Institute on Alcohol Abuse and Alcoholism
    - NIDA – National Institute of Drug Abuse
    - NIMH – National Institute of Mental Health
    - PCORI – Patient-Centered Outcomes Research Institute
    - NINDS – National Institute of Neurological Disorders and Stroke
  - Parthenon Management Group organizes the ASCP Annual Meeting.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

Susan G. Kornstein, M.D.
Steering Committee Co-chair

Mark Rapaport, M.D.
Steering Committee Co-chair

Erika Saunders, M.D.
Program Committee Co-chair

Lee Cohen, M.D.
Program Committee Co-chair
Luca Pani, M.D. is Professor of Pharmacology and Clinical Pharmacology, University of Modena and Reggio Emilia in Italy and Professor of Clinical Psychiatry, University of Miami, USA. He is also VP for Regulatory Strategy and Market Access Innovation at VeraSci in Durham, NC. As the former Director General of the Italian Medicines Agency (AIFA, 2011-2016) and former member of the Board of Directors, of the Committee for Human Medicines (CHMP) and of the Scientific Advices Working Party (SAWP) for the European Medicines Agency (EMA) in London (2010-2017), he is a recognized expert in basic and clinical pharmacology, and regulatory science with particular emphasis on health technology assessments linked with novel negotiation strategies for the reimbursement of precision medicines. In his roles he negotiated the reimbursement for the world first gene therapy (Strimvelis®) and implemented very advanced Managed Entry Agreements linked to regulatory validated registries for real life data follow-up and further evaluations based on bioinformatics. His current interests lie in virtual reality assessment tools to detect early signs of pathological ailments and designing decision tree algorithms to negotiate drug pricing under conditions of uncertainty by using clinical and sensor generated data to continuously populate the unknown variabilities of effectiveness and by linking them to outcome values dynamically recorded in real world evidence.

He is the author of over one hundred and seventy scientific publications, editor and author of several volumes and a writer of successful leisure literature. He has attended more than 1000 conferences, seminars and national and international roundtables as an invited speaker.
Dr. Nunes is Professor of Psychiatry at Columbia University Irving Medical Center and the New York State Psychiatric Institute (NYSPI), multiple Principal Investigator (mPI) of the New York Node of the NIDA Clinical Trials Network (CTN) and Co-Director of the CHOSEN Center at Columbia, founded in response to the opioid crisis and focused on the development and implementation of treatments for opioid and other substance use disorders. He currently serves as Lead or Co-Lead Investigator or mPI on new trials launched through CTN and the HEAL Initiative as well as other NIH funded studies, focused on extended-release injected and implanted formulations of medications for opioid use disorder, smart-phone app-delivered behavioral treatment for substance use disorders, and early predictors of treatment outcome. After completing medical school (University of Connecticut), internship in Internal Medicine (St Elizabeth Hospital), and residency in Psychiatry and fellowship in clinical psychopharmacology research (at Columbia/NYPSI), he has spent his career conducting clinical trials and related studies on treatment of substance use disorders and co-occurring psychiatric disorders.
Keynote Plenary Session:
Integrating New and Novel Treatments into Clinical Practice
Thursday, June 3: 3:00 PM - 4:30 PM EDT

Sarah Lisanby, M.D.
National Institute of Mental Health

Sarah Hollingsworth “Holly” Lisanby, M.D., an internationally renowned innovator of neuromodulation technologies, is Director of the Division of Translational Research at the National Institute of Mental Health (NIMH), which funds research supporting the discovery of preventions, treatments, and cures for mental illness across the lifespan. She founded and directs the Noninvasive Neuromodulation Unit in the NIMH Intramural Research Program, a pioneering translational research program specializing in the use of brain stimulation tools to measure and modulate neuroplasticity to improve mental health. Currently, she is the JP Gibbons Professor Emeritus at Duke University Department of Psychiatry and Behavioral Sciences. Previously, she was the first woman to serve as Chair of the Duke University Department of Psychiatry. She founded and directed both the Duke University and the Columbia University Divisions of Brain Stimulation, where she built interdisciplinary research programs specializing in the convergence of Psychiatry, Neuroscience and Engineering. She co-led the NIH BRAIN Initiative Team focused on large-scale neural recording and modulation devices. Dr. Lisanby’s laboratory has been continuously federally funded for over 20 years. She has been principal investigator on a series of NIH and DARPA funded studies on the development of novel neuromodulation technologies, including studies on the rational design of magnetic and electrical seizure therapies. Her team pioneered magnetic seizure therapy (MST) as a novel depression treatment from the stages of animal testing, first-in-human, and now international trials. A prolific author with over 280 scientific publications, she has received national and international recognition, including the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Max Hamilton Memorial Prize of the Collegium Internationale Neuropsychopharmacologicum (CINP), the Gerald Klerman Award from the National Depression and Manic Depression Association (NMDA), and the Eva King Killam Research Award from the American College of Neuropsychopharmacology (ACNP). Dr. Lisanby served on the FDA Neurological Devices Advisory Panel and has held key leadership positions in professional organizations including serving as President of the International Society for ECT and Neurostimulation and Chair of the American Psychiatric Association Task Force to Revise the Practice on Electroconvulsive Therapy (ECT). A Board Certified Psychiatrist, Dr. Lisanby received her dual BS in Mathematics and Psychology and her M.D. at Duke University.
Keynote Plenary Session:  
Integrating New and Novel Treatments into Clinical Practice  
Thursday, June 3: 3:00 PM - 4:30 PM EDT

Samantha Meltzer-Brody, M.D., M.P.H.  
University of North Carolina

Dr. Samantha Meltzer-Brody, M.D., M.P.H. is the Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill. She also directs the UNC Center for Women’s Mood Disorders. Dr. Meltzer-Brody is an internationally recognized physician-scientist in perinatal depression whose work investigates the epidemiologic and biological predictors of perinatal depression (PND) including genetic, neurosteroid and other neuroendocrine biomarkers as well as the impact of adverse life events in diverse populations. She has served as the academic PI for novel clinical trials developing an effective (now FDA approved) new pharmacologic treatment for postpartum depression (brexanolone). She recently received the 2020 O Max Gardner award, a UNC System Award (17 universities) for the highest faculty honor. She is also the recipient of the 2019 American Psychiatric Association Alexandra Symonds Award Women’s Mental Health.
Regularity Plenary Session:
Friday, June 4: 11:00 AM – 12:00 PM PM EDT

Michael Davis, M.D., Ph.D.
US Food and Drug Administration

Mike Davis currently serves as a Lead Physician (Clinical Team Leader) in the Division of Psychiatry at the US Food and Drug Administration (FDA). Dr. Davis completed a Medical Scientist Training Program (M.D./Ph.D.) at Case Western Reserve University, psychiatric residency training at the University of California, Los Angeles, and a research fellowship at the West Los Angeles VA Mental Illness Research, Education, and Clinical Center. His research interests focused on the development of novel therapeutics for cognitive deficits and negative symptoms associated with psychotic disorders. Prior to joining FDA in 2016, Dr. Davis was an assistant professor at Baylor College of Medicine and staff psychiatrist at the Michael E. DeBakey VA Medical Center in Houston, Texas. In his current role at the FDA, he leads a team of clinical reviewers on the review of investigational new drug applications, new drug applications for marketing approval, and post-marketing safety information. Beyond his core work duties, Dr. Davis is actively involved with the American Society of Clinical Psychopharmacology (ASCP) and the International Society for CNS Clinical Trials and Methodology (ISCTM).
Celso Arango, Prof., Ph.D.
Hospital General Universitario Gregorio Marañón

Professor Celso Arango is currently Chair of the Child and Adolescent Department of Psychiatry at Hospital General Universitario Gregorio Marañón, Complutense University in Madrid, Spain, as well as Director of the Gregorio Marañón Psychiatric and Mental Health Institute, Professor of Psychiatry at the Maryland Psychiatric Research Center of the University of Maryland in Baltimore, Adjunct Professor of Psychiatry at UCSF in San Francisco, Visiting Professor of Psychiatry at Kings College London, and Tenured Full Professor at Complutense University in Madrid.

Professor Arango completed his medical studies in 1992 at both the University of Oviedo in Spain and Manchester University in the UK. He later received his Ph.D. in Psychiatry from Complutense University of Madrid in 1997. Currently, Professor Arango’s major research interests include the neurobiology of early-onset and first-episode psychoses and neurodevelopmental psychopharmacology. He has received more than 20 awards for his work.

Dr. Arango leads one of the few research groups in the world focusing on early-onset psychosis with the largest cohort of pediatric first psychotic episode patients (see CV for more than 150 published papers with data from this cohort consisting of more than 350 children and adolescents with early-onset first-episode psychosis). He has transitioned to the field of early intervention and has created an innovative intervention program for first-episode patients and their families (PIENSA) (Calvo et al, JAACAP 2014, Calvo et al, JAACAP 2015). The program was validated in a RCT and exported to various universities in Europe and the US. He has lobbied for the creation of early intervention services in Spain, resulting in recent successful examples of new services created for this population (Arango et al, RPSM 2017; Csillag et al, Early Intervention 2017, Arango Schiz Bull 2015). Dr. Arango was the PI for the first non-commercial RCT comparing two second-generation antipsychotics in children and adolescents (Arango et al, ECAP 2009; Robles et al, Schiz Bull 2011). He has also headed one of the world’s foremost groups assessing side effects of antipsychotics in children and adolescents and has advanced the field of pediatric psychopharmacology, especially with respect to psychotic disorders (Galling et al, Jama Psychiatry 2016; Arango et al, JAACAP 2014).

He has published extensively in the highest impact factor journals in the field of pediatric schizophrenia and related psychoses (see CV for papers in Nature, Journal of Neuroscience, Lancet Psychiatry, Molecular Psychiatry, World Psychiatry, American Journal of Psychiatry, JAMA Psychiatry, etc.). He has recently put the spotlight on primary prevention of mental disorders (Arango et al, Lancet Psychiatry 2018).

Professor Arango was the first and only Scientific Director of the Spanish Psychiatric Research Network (CIBERSAM) with 24 centers and more than 400 researchers, from its creation in 2008 until 2017. The CIBERSAM coordinated the roadmap for mental health research for the European Commission (Wykes et al, Lancet Psychiatry 2015). He has participated in more than 77 competitively funded research projects and has been the coordinator or Principal Investigator for 10 EU-funded projects.
Federal Agency Updates  Plenary Session:
Friday, June 4: 12:15 PM – 2:45 PM PM EDT

Walter Koroshetz, M.D.
National Institute of Neurological Disorders and Stroke

Dr. Koroshetz serves as Director of the National Institute of Neurological Disorders and Stroke. He joined NINDS in 2007 as Deputy Director and has held leadership roles in a number of NIH and NINDS programs including co-leading the NIH’s BRAIN Initiative, the NIH Blueprint for Neuroscience, the Traumatic Brain Injury Center collaboration between the NIH intramural and the Uniformed Health Services University, the Helping to End Addiction Long Term (HEAL) Initiative, the Common Fund’s Undiagnosed Disease and the Acute to Chronic Pain Transition programs, and he was instrumental in founding the NIH Office of Emergency Care Research.

Before joining NINDS, Dr. Koroshetz served as Vice Chair of the neurology service and Director of stroke and neurointensive care services at Massachusetts General Hospital (MGH). He was a professor of Neurology at Harvard Medical School (HMS) and led neurology resident training at MGH between 1990 and 2007. Over that same period, he co-directed the HMS Neurobiology of Disease Course with Drs. Edward Kravitz and Robert H Brown.

A native of Brooklyn, New York, Dr. Koroshetz graduated from Georgetown University and received his medical degree from the University of Chicago. He trained in internal medicine at the University of Chicago and Massachusetts General Hospital. He then trained in Neurology and Neuroscience at MGH and Harvard Neurobiology focusing on how synaptic mechanisms might contribute to neuronal death. His early research in the lab and clinic focused on Huntington’s disease and with the team at MGH performed the first study of pre-symptomatic testing based on linkage analysis. A major focus of his clinical research career was the development of measures in patients that reflect the underlying biology of their conditions. This led to brain the development and validation of imaging techniques including Magnetic Resonance (MR) spectroscopy in Huntington’s disease; diffusion/perfusion MR and CT X-ray angiography and perfusion imaging in stroke. These stroke imaging tools are now commonplace in stroke care. Guided by these tools he pioneered acute clot removal for acute stroke patients with large artery occlusion which is now practiced at Comprehensive stroke centers around the country. Through his work with the American Academy of Neurology, American Stroke Association and ACGME, he played a significant role in the revolution in acute stroke care in the US and the growth of the neurointensive care field.
Dr. Gordon received his M.D./Ph.D. degree at the University of California, San Francisco and completed his Psychiatry residency and research fellowship at Columbia University. He joined the Columbia faculty in 2004 as an Assistant Professor in the Department of Psychiatry where he conducted research, taught residents, and maintained a general psychiatry practice. In September of 2016, he became the Director of the National Institute of Mental Health. Dr. Gordon’s research focuses on the analysis of neural activity in mice carrying mutations of relevance to psychiatric disease. His lab studies genetic models of these diseases from an integrative neuroscience perspective, focused on understanding how a given disease mutation leads to a behavioral phenotype across multiple levels of analysis. To this end, he employs a range of systems neuroscience techniques, including in vivo anesthetized and awake behaving recordings and optogenetics, which is the use of light to control neural activity. His work has direct relevance to schizophrenia, anxiety disorders, and depression. Dr. Gordon’s work has been recognized by several prestigious awards, including The Brain and Behavior Research Foundation – NARSAD Young Investigator Award, the Rising Star Award from the International Mental Health Research Organization, the A.E. Bennett Research Award from the Society of Biological Psychiatry, and the Daniel H. Efron Research Award from the American College of Neuropsychopharmacology.
George Koob, Ph.D.
National Institute on Alcohol Abuse and Alcoholism

George F. Koob, Ph.D., is an internationally-recognized expert on alcohol and stress, and the neurobiology of alcohol and drug addiction. He is the Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), where he provides leadership in the national effort to reduce the public health burden associated with alcohol misuse. As NIAAA Director, Dr. Koob oversees a broad portfolio of alcohol research ranging from basic science to epidemiology, diagnostics, prevention, and treatment.

Dr. Koob earned his doctorate in Behavioral Physiology from Johns Hopkins University in 1972. Prior to taking the helm at NIAAA, he served as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders and Director of the Alcohol Research Center at the Scripps Research Institute. Early in his career, Dr. Koob conducted research in the Department of Neurophysiology at the Walter Reed Army Institute of Research and in the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies. He was a post-doctoral fellow in the Department of Experimental Psychology and the MRC Neuropharmacology Unit at the University of Cambridge.

Dr. Koob began his career investigating the neurobiology of emotion, particularly how the brain processes reward and stress. He subsequently applied basic research on emotions, including on the anatomical and neurochemical underpinnings of emotional function, to alcohol and drug addiction, significantly broadening knowledge of the adaptations within reward and stress neurocircuits that lead to addiction. This work has advanced our understanding of the physiological effects of alcohol and other substance use and why some people transition from use to misuse to addiction, while others do not. Dr. Koob has authored more than 750 peer-reviewed scientific papers and is a co-author of The Neurobiology of Addiction, a comprehensive textbook reviewing the most critical neurobiology of addiction research conducted over the past 50 years.

Dr. Koob is the recipient of many prestigious honors and awards recognizing his contributions to research, mentorship, and international scientific collaboration. These include: the Research Society on Alcoholism (RSA) Seixas Award for extraordinary service in advancing alcohol research; the RSA Distinguished Investigator Award; the RSA Marlatt Mentorship Award; the Daniel Efron Award for excellence in basic research and the Axelrod Mentorship Award, both from the American College of Neuropsychopharmacology; the NIAAA Mark Keller Award for his lifetime contributions to our understanding of the neurobiology of alcohol use disorder; and an international prize in the field of neuronal plasticity awarded by La Fondation Ipsen. He was recently honored by the government of France with the insignia of Chevalier de la Légion d’honneur (Knight of the Legion of Honor) for developing scientific collaborations between France and the United States.
Nora D. Volkow, M.D., is the Director of the National Institute on Drug Abuse (NIDA), which supports most of the world’s research on the health aspects of drug abuse and addiction. Dr. Volkow’s scientific research was instrumental in demonstrating that drug addiction is a disease of the human brain and, as NIDA Director, her work has promoted research that improves the prevention and treatment of substance use disorders. As a research psychiatrist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic and addictive effects of abusable drugs. Her studies documented disruption of the dopamine system in addiction with its consequential functional impairment of frontal brain regions involved with motivation, executive function and self-regulation. She has also made important contributions to the neurobiology of obesity, and ADHD and has published more than 820 peer-reviewed articles, written more than 100 book chapters and non-peer-reviewed manuscripts, co-edited a Neuroscience Encyclopedia and edited four books on neuroimaging for mental and addictive disorders.
Dr. Ramsawh is a Senior Program Officer within the Science division at the Patient-Centered Outcomes Research Institute (PCORI). In this role, she supports the Clinical Effectiveness Research priority area. Her responsibilities include strategic decision-making to advance PCORI’s patient-centered research agenda, developing funding announcements, and awarding and managing a portfolio of funded projects. Before PCORI, she was a research psychologist with the Henry M. Jackson Foundation for the Advancement of Military Medicine, and a research assistant professor in the Department of Psychiatry at the Uniformed Services University of the Health Sciences. In this position, she conducted research in the areas of psychiatric epidemiology and military mental health, including risk factors for suicidal behavior in the military. In addition, she has clinical and research expertise in the phenomenology, course, and cognitive-behavioral treatment of anxiety disorders and insomnia. Dr. Ramsawh received a Ph.D. in clinical psychology from Boston University. She completed her pre-doctoral internship at Zucker Hillside Hospital/Long Island Jewish Medical Center, and postdoctoral fellowships at both Brown University and the University of California San Diego. She maintains licensure as a psychologist in the state of California.
ACKNOWLEDGEMENTS

New Investigator Award Program Chairs

Mark H. Rapaport, M.D.  Christopher Sarampote, Ph.D.

Program Chairs

Erika Saunders, M.D.  Lee Cohen, M.D.

Steering Committee Chairs

Susan G. Kornstein, M.D.  Mark H. Rapaport, M.D.
**PROGRAM COMMITTEE**

Scott Aaronson, M.D.*
Sheppard Pratt Health Systems

Mohammed Ahmed, M.D.
University of California, San Diego

Amit Anand, M.D.
Cleveland Clinic Lerner School of Medicine of Case Western University

Pratik Bahekar, M.D.
Yale-New Haven Psychiatric Hospital

Anahita Bassir Nia, M.D.*
Yale University School of Medicine

Theadia L. Carey, M.D.*
Detroit Wayne Health Authority

Lawrence Cohen, Pharm.D.
University of North Texas Health Science Center

**New Investigator Alumni**

Lynn Crismon, Pharm.D.*
The University of Texas at Austin

Larry Culpepper, M.D., M.P.H.
Boston University

**Cristina Cusin, M.D.**
Massachusetts General Hospital

Maurizio Fava, M.D.
Massachusetts General Hospital

**Bharathi Gadad, Ph.D.**
Texas Tech University Health Science Center

Bradley Gaynes, M.D.*
University of North Carolina

**Srinath Gopinath, M.D.**
UCONN Health Center

**Representing ASCP CME Committee**
Vikas Gupta, M.D., M.P.H.*
ECU

Ahmad Hameed, M.D.
Pennsylvania State College of Medicine

Usman Hameed, M.D.
Penn State Hersey Medical Center

Ebrahim Haroon, M.D.
Emory University School of Medicine

Michael Henry, M.D.
Massachusetts General Hospital

Dan Iosifescu, M.D.
Nathan S Kline Institute/New York University School of Medicine

Ayana Jordan, M.D., Ph.D.
Yale University School of Medicine

Susan Kornstein, M.D.
Virginia Commonwealth University

Rajnish Mago, M.D.*
Simple and Practical Mental Health

Tim Mariano, M.D., Ph.D.
Woebot Health

Sanjay Mathew, M.D.
Baylor College of Medicine

Brian Mickey, M.D., Ph.D.
University of Utah School of Medicine

Francisco Moreno, M.D.
University of Arizona

Charles Nemerooff, M.D., Ph.D.
The University of Texas at Austin

Andrew Nierenberg, M.D.
Massachusetts General Hospital

Minkyung Park, M.D.
UTSW Medical Center Dallas

Mark Pollack, M.D.
Rush University Medical Center

Rajiv Radhakrishnan, M.D.
Yale School of Medicine

Shamecca Scott, Psy.D.
MindSet, LLC

Jair Soares, M.D., Ph.D.
University of Texas School of Medicine at Houston

Oleg Tcheremissine, M.D.
Atrium Health

Madhukar Trivedi, M.D.
University of Texas Southwestern Medical Center

Christine Ulbricht, M.P.H., Ph.D.
University of Massachusetts Medical School

Carlos A. Zarate, M.D.
National Institute of Mental Health

Mark Zimmerman, M.D.*
Brown University

*Representing ASCP CME Committee
Ross Baker, Ph.D.
Otsuka Pharmaceuticals

Lee Cohen, M.D.
Massachusetts General Hospital

Ella Daly, M.D.
Johnson & Johnson PRD

Lori Davis, M.D.
Tuscaloosa VA Medical Center

Bryan Dirks, M.D.
ACADIA Pharmaceuticals Inc.

Daniel Falk, Ph.D.
NIAAA/NIH

Tiffany Farchione, M.D.
US Food and Drug Administration

Marlene Freeman, M.D.
Massachusetts General Hospital,
Ammon-Pinizzotto Center for Women’s
Mental Health

David J. Kupfer, M.D.
University of Pittsburgh School of
Medicine

Valentina Mantua, M.D.
Center for Drug Evaluation and
Research, Food and Drug Administration

Stephen Marder, M.D.
Semel Institute at UCLA

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Francisco Moreno, M.D.
University of Arizona

John Newcomer, M.D.
Thriving Mind South Florida

Luca Pani, M.D.
University of Miami

Mark Pollack, M.D.
Myriad Neuroscience

Erika Saunders, M.D.
Penn State College of Medicine, Penn
State Milton S. Hershey Medical Center

Holly Swartz, M.D.
University of Pittsburgh School of
Medicine

Madhukar Trivedi, M.D.
University of Texas Southwestern
Medical Center

New Investigator Alumni

*Representing ASCP CME Committee
ASCN OFFICERS AND BOARD

★ Madhukar Trivedi, M.D.
ASCN President
UT Southwestern Medical Center

Michael E. Thase, M.D.
ASCN Past President
University of Pennsylvania

Leslie Citrome, M.D., M.P.H.
ASCN Treasurer and President Elect
New York Medical College

John Newcomer, M.D.
ASCN Past Treasurer
South Florida Behavioral Health Network

Trisha Suppes, M.D., Ph.D.
ASCN Treasurer Elect
Stanford University

Scott Aaronson, M.D.*
Sheppard Pratt Health System

Joseph Calabrese, M.D.
University Hospitals Cleveland Medical Center

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

★ Kristina Deligiannidis, M.D.
Zucker Hillside Hospital; Feinstein Institute for Medical Research; Hofstra Northwell School of Medicine

Marlene Freeman, M.D.
Massachusetts General Hospital, Ammon-Pinizzotto Center for Women’s Mental Health

★ Joseph Goldberg, M.D.*
Icahn School of Medicine at Mount Sinai

★ Dan Iosifescu, M.D.
Nathan S Kline Institute/New York University School of Medicine

John Kane, M.D.
The Zucker Hillside Hospital

Susan Kornstein, M.D.
Virginia Commonwealth University, Board Member-elect

Matthew Macaluso, D.O.
University of Alabama at Birmingham

Stephen Marder, M.D.
Semel Institute at UCLA

Sanjay Mathew, M.D.
Baylor College of Medicine

★ Francisco Moreno, M.D.
University of Arizona

★ George Papakostas, M.D.
Massachusetts General Hospital

★ Katharine Phillips, M.D.
Weill Cornell Medical College/New York-Presbyterian Hospital

★ Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine, Board Member-elect

★ New Investigator Alumni
*Representing ASCN CME Committee
Ellen Frank is Distinguished Professor Emeritus of Psychiatry at the University of Pittsburgh School of Medicine and Chief Clinical Research Officer of HealthRhythms, Inc., a mobile technology company developing smartphone-based behavioral monitoring for clinical trials and digital intervention platforms.

For more than 35 years, Dr. Frank’s work focused on a better understanding of mood disorders and their treatment. Her 1990 study of maintenance therapies in recurrent unipolar depression is considered a classic in the field. She and her colleagues subsequently demonstrated the preventive efficacy of interpersonal and social rhythm therapy (IPSRT), a psychosocial intervention originally developed for adult outpatients with bipolar I disorder and subsequently modified for a broader range of mood disorders, age groups and treatment settings. Since transitioning to emeritus status, Dr. Frank has focused her attention on the development and testing of smartphone-based digital biomarkers and therapeutic platforms based on the social rhythm regulation conceptual model.

An expert on mood disorders and their treatment, Dr. Frank has published more than 475 peer-review papers, in addition to over 100 book chapters and books. In 1999, Dr. Frank was elected to the National Academy of Medicine.
Congratulations!
Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award

**Maurizio Fava, M.D.**
Massachusetts General Hospital, Harvard Medical School

Dr. Fava obtained his M.D. from the University of Padova School of Medicine where he completed residency training in endocrinology. He completed residency training in psychiatry at Mass General. He founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry.

Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $95,000,000. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.

Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts.
Congratulations!

Recipients of the Nina Schooler Early Career Research Award

Jonathan Young, M.D.
Duke University School of Medicine
2020-2021
Visit Dr. Young’s Poster on Wednesday, June 02, 2021, titled *Electroconvulsive Therapy Changes Immunological Markers in Patients with Major Depressive Disorder.* Poster W18

Reilly Kayser, M.D.
Columbia University/New York State Psychiatric Institute
2019-2020

Sunny Tang, M.D.
Zucker School of Medicine at Hofstra/Northwell
2018-2019
Congratulations!

NEW INVESTIGATOR AWARDEES

Sri Mahavir Agarwal, M.D., Ph.D.
Centre for Addiction and Mental Health (CAMH), Canada

Helene Altmann, B.S.
Department of Psychiatry, University of Pittsburgh

Anahita Bassir Nia, M.D.
Yale University School of Medicine

Walter Dunn, M.D., Ph.D.
West Los Angeles VA Medical Center/UCLA

Rachel Fremont, M.D.
College of Physicians and Surgeons, Columbia University/New York State Psychiatry

Daniel Guinart, M.D.
The Zucker Hillside Hospital

Rishab Gupta, M.D.
Brigham and Women’s Hospital, SUNY Downstate Medical Center

Ming-Fen Ho, Ph.D.
Mayo Clinic

Holly Hunsberger, Ph.D.
Columbia University & New York State Psychiatric Institute

Christoph Kraus, Ph.D.
Medical University of Vienna

Eric Lin, M.D.
VA Boston Healthcare System (116A)

Anahit Mkrtchian, B.Sc., M.Sc.
University College London, Institute of Cognitive Neuroscience

Lina Montoya, M.A.
UC Berkeley

Mercy Mumba, Ph.D.
University of Alabama

Jessica Rohr, Ph.D.
The Menninger Clinic

James Rucker, M.D., Ph.D.
King’s College London, Institute of Psychiatry

Mercedes Szpunar, M.D., Ph.D.
Harvard Medical School, Massachusetts General Hospital

Hideaki Tani, M.D., Ph.D.
Centre of Addiction and Mental Health

Fumihiko Ueno, M.D.
Centre for Addiction and Mental Health

Corinde Wiers, Ph.D.
University of Pennsylvania
JOIN THE CONVERSATION!

#ASCP
#2021ASCPVirtual

#ClinicalPractice
#ASCP21

@ASCPorg
Thank you!

Intra-Cellular Therapies
Sunovion
Supernus

ASCP would like to acknowledge the generosity of the above companies whose unrestricted educational grants have contributed to the overall quality of this meeting.
Disclosures are available for all ASCP Annual Meeting presenters online at [www.ASCPMeeting.org](http://www.ASCPMeeting.org).

**Continuing Education Credits** are available for physicians, pharmacists, and psychologists. **Self-assessment maintenance of certification credits** are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey will be emailed to you at the completion of the meeting and will be available online at [www.ASCPMeeting.org](http://www.ASCPMeeting.org).

**Surveys for continuing education credit must be submitted no later than Saturday, July 31, 2021.** It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

**The American Board of Psychiatry and Neurology** has reviewed the annual meeting and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. For the enduring portion, you must complete the entire chosen session. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Physicians, Nurses and Pharmacists (ACCME, ANCC & ACPE)

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Society of Clinical Psychopharmacology (ASCP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide education for the healthcare team. Successful completion of the this program qualifies for up to 16.25 live AMA PRA Category 1 Credits™ live and 70.00 enduring AMA PRA Category 1 Credits™ enduring for physicians, 16.25 live and 70.00 enduring ANCC contact hours for nurses and 16.25 live and 70.00 enduring knowledge-based contact hours for pharmacists. **Live Event UAN: JA4008163-9999-21-098-L04-P. Enduring Event UAN: JA4008163-9999-21-072-H04-P.**

**Pharmacists Note:** The only official Statement of Credit is the one you pull from CPE Monitor.

Amedco LLC certifies that the attendee named above has participated in the enduring material activity titled 2021 ASCP Annual Meeting Live & Enduring Material between June 4, 2021 and July 31, 2021 and is awarded the number of credit hours listed above.

### New York Board for Psychology (NY PSY)

Amedco is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031.

**Live: 16.25 hours - Enduring: 70.00 hours**

The 16.25 live hours cannot also be claimed as enduring hours.

**All participants who request continuing education credits by Saturday, July 31, 2021, should expect to receive their statement of credits emailed to them immediately. MOC certificates will be emailed in August.**

**The Meeting Evaluation Survey** will be available at [www.ASCPMeeting.org](http://www.ASCPMeeting.org). We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2020 meeting is appreciated as we strive to improve the meeting each year.
SAVE THE DATE!

May 31 – June 3, 2022
Fairmont Scottsdale Princess